Caricamento...
Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study
Tenapanor (RDX5791/AZD1722) is a minimally systemic small‐molecule inhibitor of the sodium/hydrogen exchanger NHE3. Tenapanor acts in the gut to reduce absorption of sodium and phosphate. This phase 1 open‐label, 3‐way crossover study (NCT02226783) evaluated the effect of food on the pharmacodynamic...
Salvato in:
| Pubblicato in: | Clin Pharmacol Drug Dev |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5599956/ https://ncbi.nlm.nih.gov/pubmed/28339149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.341 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|